Cambridge Investment Research Advisors
SPRY icon

Cambridge Investment Research Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Cambridge Investment Research Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$700K Hold
87,161
– – ﹤0.01% 2501
2025
Q4 		$1.01M Hold
87,161
– – ﹤0.01% 2083
2025
Q3 		$876K Sell
87,161
-1
-0% -$14 ﹤0.01% 2151
2025
Q2 		$1.52M Buy
87,162
+4
+0% +$58 ﹤0.01% 1642
2025
Q1 		$1.1M Hold
87,158
– – ﹤0.01% 1787
2024
Q4 		$920K Hold
87,158
– – ﹤0.01% 1937
2024
Q3 		$1.26M Buy
+87,158
New +$1.04M ﹤0.01% 1690

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Cambridge Investment Research Advisors's SPRY Position: Q1 2026 in Review

Cambridge Investment Research Advisors held its ARS Pharmaceuticals (SPRY) position steady in Q1 2026 at 87,161 shares worth $700K. The position accounts for ﹤0.01% of the portfolio, ranked #2501.

Cambridge Investment Research Advisors first reported a position in SPRY in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.52M in Q2 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Cambridge Investment Research Advisors held 87,161 shares of ARS Pharmaceuticals worth $700K as of Q1 2026.
  • Cambridge Investment Research Advisors left its ARS Pharmaceuticals share count unchanged in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #2501 holding.
  • Cambridge Investment Research Advisors first reported a position in ARS Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Cambridge Investment Research Advisors's ARS Pharmaceuticals position peaked at $1.52M in Q2 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.